Clinical trials: Adenovirus Infection
Wounds and Injuries, Diabetes
Gene Therapy to Improve Wound Healing in Patients With Diabetes
Patients with diabetes may develop chronic wounds that respond poorly to treatment. Gene therapy with the platelet-derived growth factor-B gene has been shown to help with the healing of chronic wounds.
- Conditions
- Wounds and Injuries, Diabetes, Diabetic Foot Ulcers, Foot Wounds
- Trial name
- NCT00065663
- Testing
- GAM501
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tissue Repair Company
Pancreatic Adenocarcinoma, Ovarian Cancer
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning.
- Conditions
- Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer
- Trial name
- NCT03225989
- Testing
- LOAd703
- Where
- 2 sites in Sweden
- Volunteers
- 47 people
- Sponsor
- Lokon Pharma AB
Adenovirus
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
The objective is data collection to determine background rates of adenovirus (AdV) progression and mortality in subjects with Adenovirus (AdV) infection and/or disease.
- Trial name
- NCT02420080
- Testing
- Brincidofovir
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jazz Pharmaceuticals
Prostate Cancer
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
A Phase Ib2, multicenter, randomized, double-blind, placebo-controlled safety and efficacy study evaluating different regimens of the immunotherapeutic drug, Mobilan (M-VM3), in patients with prostate cancer.
- Trial name
- NCT02844699
- Testing
- Mobilan (M-VM3)
- Where
- 4 sites in Russia
- Volunteers
- 24 people
- Sponsor
- Panacela Labs LLC
Adenoviral Conjunctivitis
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis
The purpose of this study is to evaluate the clinical and microbiological efficacy and safety of NVC-422 compared to vehicle for adenoviral conjunctivitis.
- Trial name
- BAYnovation™ (NCT01532336)
- Testing
- NVC-422 Solution, 0.3%, NVC-422 Vehicle Solution
- Where
- 58 sites in United States, Brazil and 2 more
- Volunteers
- 500 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
Prostate Cancer
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer.
- Trial name
- NCT00116155
- Testing
- CV787 (CG7870)
- Sponsor
- Cell Genesys
Healthy Volunteer, HIV Vaccine
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
The purpose of this study is to test experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus vector. The adenovirus vector may help the vaccines stimulate an immune response.
- Trial name
- NCT02771730
- Testing
- Ad4-mgag, Ad4-EnvC150, AIDSVAX B/E
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Severe Haemophilia A
Gene Therapy Study in Severe Haemophilia A Patients (270-201)
This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, dose escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec (an Adenovirus-Associated Virus based gene therapy…
- Trial name
- NCT02576795
- Testing
- valoctocogene roxaparvovec
- Where
- 5 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- BioMarin Pharmaceutical
Influenza
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 Hemagglutinin (HA) Adenoviral-Vector Based Seasonal Influenza Vaccine and…
- Trial name
- NCT02918006
- Testing
- VXA-A1.1, Fluzone®
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Vaxart
Respiratory Syncytial Virus
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age
The purpose of this study is to assess the safety and reactogenicity of an intramuscular regimen of 3 doses of 2.5*10^10 viral particles (vp) of adenovirus serotype 26 based respiratory syncytial virus pre-fusion protein…
- Trial name
- NCT03606512
- Testing
- Ad26.RSV.preF, Nimenrix
- Where
- 25 sites in Australia, Brazil and 6 more
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients
Hepatitis B virus (HBV) infection is a worldwide health problem. It has been proved that the persistence of HBV is associated with the failure to stimulate an efficient HBV-specific immune response.
- Trial name
- NCT04168333
- Testing
- T101 Group
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Norovirus Infections
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
A Phase 1b, multicenter, randomized, double-blind, placebo-controlled study to determine the safety and immunogenicity of an adenoviral-vector based oral norovirus vaccine expressing GI.1 VP1 administered orally to healthy older…
- Trial name
- VXA-NVV-104 (NCT04854746)
- Testing
- VXA-GI.1.NN
- Where
- 3 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vaxart
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma
- Trial name
- NCT02045602
- Testing
- VCN-01, Gemcitabine, Abraxane®
- Where
- 5 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Theriva Biologics SL
Acute Adenoviral Keratoconjunctivitis
Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis
The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.
- Trial name
- NCT01156025
- Testing
- GV550
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Laboratoires Thea
Viral Conjunctivitis
ADenoVirus Initiative Study in Epidemiology in UK
The objectives of this study is to assess the characteristics and frequency of adenovirus conjunctivitis in a population of male and female patients from one year of age who present signs and symptoms of acute conjunctivitis.
- Trial name
- NCT02112773
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- NicOx
Influenza A Subtype H5N1 Infection
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe…
- Trial name
- NCT00755703
- Testing
- Pandemic Influenza Vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Adenovirus Infections, Human
Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients
To depict the incidence, outcomes and standards of care (SoC) of adenovirus (AdV) infections and associated practice patterns in allogeneic hematopoietic cell transplant recipients.
- Trial name
- AdVance (NCT04285788)
- Volunteers
- 216 people
- Sponsor
- Jazz Pharmaceuticals
Malignant Solid Tumour
ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers
The purpose of the study is to investigate the safety and the recommended dose for later use of an oncolytic adenovirus CGTG-102 in combination with low-dose oral cyclophosphamide in the treatment of advanced cancers.
- Trial name
- NCT01598129
- Testing
- ONCOS-102
- Where
- Finland
- Volunteers
- 12 people
- Sponsor
- Targovax Oy
Transitional Cell Carcinoma, Bladder Cancer
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the…
- Conditions
- Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors
- Trial name
- BOND (NCT01438112)
- Testing
- CG0070 Adenovirus Vector, Control Arm: Quadruple Choice
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- CG Oncology, Inc.
COVID - 19, SARS CoV-2
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations.
- Trial name
- NCT07416539
- Testing
- COVID-19 Vaccines
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy